Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis
{{output}}
Therapeutic modulation of sepsis-induced immune dysfunction by targeting lymphocyte dysfunction with recombinant IL-7 (rIL-7) and anti-PD-1 (e.g. nivolumab) has shown promise in preclinical and early clinical studies. Prior to conducting large randomized contr... ...
